5-ht2a and/or 5-ht2c receptor agonists
AssigneeDiamond Therapeutics Inc.
InventorMethvin ISAAC
Life of this patent
Estimating the term…
Abstract
Provided herein are heterocyclic compounds, processes for their preparation, compositions comprising said compounds, and use in therapy. More particularly, the present disclosure relates to fluorinated and/or deuterated analog useful in the treatment of diseases, disorders or conditions treatable by modulating the 5-HT2 receptor subtypes.
Claims21
1-153. (canceled)
A compound, or pharmaceutically acceptable salt or solvate thereof, having the structure of Formula (I):
- wherein
- R1, R2 and R3 are each independently selected from H and C1-C6 optionally substituted alkyl;
- and
- ring A is an optionally substituted heteroaryl ring selected from
- wherein
- * represents the points of attachment;
- R4 and R5 are independently selected from H, halo, CN, C1-4alkyl, C1-4haloalkyl, OC1-4alkyl, OC1-4haloalkyl, O(optionally substituted C3-10 carbocycle),
- O(optionally substituted C3-10 aryl), and N(R8R9);
- R6 and R7 are independently selected from H and C1-C6 optionally substituted alkyl;
- and
- R8 and R9 are joined to form, together with the atom therebetween, a C3-12heterocycloalkyl, optionally comprising one additional heteromoiety selected from N(R10), O, S, S(O) and SO2, and optionally substituted with one or more substituents selected from halo, OH, C1-6alkyl, C3-6cycloalkyl, aryl, C5-6heteroaryl, C3-6 heterocycloalkyl, C1-6 alkyleneC3-6cycloalkyl, C1-6alkylenearyl, C1-6alkyleneC5-6heteroaryl, C1-6alkyleneC3-6heterocycloalkyl, C(O)C1-6alkyl, OC1-6alkyl, OC1-6alkyleneOC1-6alkyl, C(O)NH2, C(O)NH(C1-6alkyl), C(O)N(C1-6alkyl)(C1-6alkyl), NHC(O)C1-6alkyl, N(C1-6alkyl)C(O)C1-6alkyl, NH2, NH(C1-6alkyl), N(C1-6alkyl)(C1-6alkyl), SC1-6alkyl, S(O)C1-6alkyl, and SO2C1-6alkyl, wherein
- R10 is selected from hydrogen, C1-6alkyl, C3-6cycloalkyl, aryl, C5-6heteroaryl, C3-6 heterocycloalkyl, C1-6 alkyleneC3-6cycloalkyl, C1-6alkylenearyl, C1-6alkyleneC5-6heteroaryl, C1-6alkyleneC3-6heterocycloalkyl, C(O)C1-6alkyl, C(O)NH2, C(O)NH(C1-6alkyl), C(O)N(C1-6alkyl)(C1-6alkyl), S(O)C1-6alkyl, and SO2C1-6alkyl;
- and
- all alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups of the optional substituents on the C3-12heterocycloalkyl formed by R8 and R9 are optionally substituted with one or more substituents selected from halo, C1-6alkyl, OC1-6alkyl, C1-6haloalkyl, and OC1-6haloalkyl.
A compound, or pharmaceutically acceptable salt or solvate thereof, as provided in Table 1.
A compound, or pharmaceutically acceptable salt or solvate thereof, selected from
Dependencies are inferred from the claim text.